Skip to main content
Premium Trial:

Request an Annual Quote

From AFCS, Painstaking Pathways


I enjoyed reading Nat Goodman’s article “Can’t Get There From Here” in the latest issue of GT (June ’03). He did well in presenting the problems of navigating not only through signaling pathways, but also through the varied websites that are attempting to represent them.

I want to point out that the AfCS-Nature Signaling Gateway does indeed contain a few pathway maps within its Molecule Page section ( It is only a modest set of pathways at the moment, but we plan on expanding the list as well as developing more dynamic ways of using them to view experimental data and linking them to the Molecule Pages.

We are also exploring new ways of representing complex pathways to make navigation easier and more meaningful (check out a recent paper we posted on the subject: We hope to create a valuable resource for signal transduction scientists, so keep checking our site for new developments.


Gilberto R. Sambrano, PhD
System Committees Coordinator
Alliance for Cellular Signaling

Send us your thoughts

Don’t be shy. Tell us what you think. Send e-mail to [email protected]
or mail to: Editor, Genome Technology, PO Box 998, New York, NY 10272-0998

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.